http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103565783-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-055 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 |
| filingDate | 2012-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103565783-B |
| titleOfInvention | The application in voltage gated k+ channel blocker agonist prepared by hexachlorophene |
| abstract | The invention provides the application of a kind of hexachlorophene in preparation KCNQ agonist; In addition, present invention also offers a kind of hexachlorophene in preparation as the application in the medicine of KCNQ agonist; Wherein, in above-mentioned application, described KCNQ agonist can be KCNQ1 agonist, KCNQ1/KCNE1 agonist, KCNQ2 agonist or KCNQ2/KCNQ3 agonist.Present invention show hexachlorophene and there is enhancing KCNQ1/KCNE1 electric current, promote Single Cardiac Cell repolarization, reach potential duration under reach, treat ARR effect; Hypotype potentiation shows, hexachlorophene strengthens KCNQ and M electric current, by strengthening KCNQ2 electric current and KCNQ2/KCNQ3 different aggressiveness Current Regulation level of membrane potential, weaken the effect that action potential provides frequency, achieve the application of hexachlorophene in the medicine being epilepsy target spot is treated with KCNQ in preparation, reach antiepileptic efficacy. |
| priorityDate | 2012-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.